close
Add to watchlist
Enzon Pharmaceuticals Inc (ENZN) Healthcare, Biotechnology & Drugs
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products. Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkin's lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines. The company was founded in 1981 and is based in Bridgewater, New Jersey.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 6.97 |
| Volume | 119819 |
| Volume Avg | 200169 |
| 52 Week High | 11.82 |
| 52 Week Low | 6.13 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.45 |
| EPS change Q/Q | -99.67% |
| EPS change Q/Q Yr ago | -99.74% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | 31.67% |
| REV change Q/Q | -81.61% |
| REV change Q/Q Yr ago | -69.13% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |